Abpro Holdings, a biotechnology company, submitted an investigational new drug (IND) application for ABP-102/CT-P72 to the FDA.
The T cell engager ABP-102/CT-P72 is designed for HER2-positive cancers such as breast and gastric cancers.
The submission marks a significant milestone for Abpro's immuno-oncology pipeline and signifies a collaboration with Celltrion, Inc.
Phase 1 Clinical Trial Initiation
The submission of the IND supports the upcoming phase 1 clinical trial in 1H 2026 for HER2-positive cancers.
Preclinical Studies Highlights
Preclinical studies show enhanced tumor selectivity and a favorable safety profile of ABP-102/CT-P72.
Collaborative Development
The IND submission is a joint effort between Abpro Holdings and Celltrion, Inc. for the development of ABP-102/CT-P72.
- The preclinical results exhibited selective activity in HER2-high tumor models and promising tolerability in non-human primates.
- The submission positions Abpro closer to delivering a selective therapeutic option for patients with limited treatment choices for HER2-positive solid tumors.
The submission of the IND for ABP-102/CT-P72 demonstrates Abpro's commitment to advancing innovative therapies for challenging diseases. This milestone paves the way for potential breakthroughs in immuno-oncology treatments.